NCT02058602View on ClinicalTrials.gov

Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 3, 2013

Primary Completion Date

July 11, 2016

Study Completion Date

July 11, 2016

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
OTHER

Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months

Patients are receiving no treatment on this study and there is no investigational product involved.

Trial Locations (1)

2650

GSK Investigational Site, Edegem

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

University Hospital, Antwerp

OTHER

lead

GlaxoSmithKline

INDUSTRY

NCT02058602 - Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients | Biotech Hunter | Biotech Hunter